Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study

AIMS/HYPOTHESIS: The study aimed to examine the efficacy of 12 weeks of monthly evolocumab or placebo in lowering LDL-cholesterol (LDL-C) in individuals with type 2 diabetes and hypercholesterolaemia or mixed dyslipidaemia and on a maximum-tolerated statin of at least moderate intensity. METHODS: Fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenson, Robert S., Daviglus, Martha L., Handelsman, Yehuda, Pozzilli, Paolo, Bays, Harold, Monsalvo, Maria Laura, Elliott-Davey, Mary, Somaratne, Ransi, Reaven, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509076/
https://www.ncbi.nlm.nih.gov/pubmed/30953107
http://dx.doi.org/10.1007/s00125-019-4856-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509076/
https://www.ncbi.nlm.nih.gov/pubmed/30953107
http://dx.doi.org/10.1007/s00125-019-4856-7

Ejemplares similares